Encephalopathy and Complex Hyperkinesia in a Patient with Severe Acute Respiratory Syndrome Coronavirus-2 Infection by Li, Wenyang et al.
University of Kentucky 
UKnowledge 
Neurology Faculty Publications Neurology 
1-12-2021 
Encephalopathy and Complex Hyperkinesia in a Patient with 
Severe Acute Respiratory Syndrome Coronavirus-2 Infection 
Wenyang Li 
University of Kentucky, wenyang.li@uky.edu 
Elif Pinar Coskun 
University of Kentucky, Pinar.Coskun@uky.edu 
Rolando Berger 
University of Kentucky, rberger@email.uky.edu 
John T. Slevin 
University of Kentucky, jslevin@uky.edu 
L. Creed Pettigrew 
University of Kentucky, cpetti@uky.edu 
Follow this and additional works at: https://uknowledge.uky.edu/neurology_facpub 
 Part of the Internal Medicine Commons, Neurology Commons, and the Neurosciences Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Li, Wenyang; Coskun, Elif Pinar; Berger, Rolando; Slevin, John T.; and Pettigrew, L. Creed, "Encephalopathy 
and Complex Hyperkinesia in a Patient with Severe Acute Respiratory Syndrome Coronavirus-2 Infection" 
(2021). Neurology Faculty Publications. 79. 
https://uknowledge.uky.edu/neurology_facpub/79 
This Letter to the Editor is brought to you for free and open access by the Neurology at UKnowledge. It has been 
accepted for inclusion in Neurology Faculty Publications by an authorized administrator of UKnowledge. For more 
information, please contact UKnowledge@lsv.uky.edu. 
Encephalopathy and Complex Hyperkinesia in a Patient with Severe Acute 
Respiratory Syndrome Coronavirus-2 Infection 
Digital Object Identifier (DOI) 
https://doi.org/10.14802/jmd.20084 
Notes/Citation Information 
Published in Journal of Movement Disorders. 
Copyright © 2021 The Korean Movement Disorder Society 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-
Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 
This letter to the editor is available at UKnowledge: https://uknowledge.uky.edu/neurology_facpub/79 
Copyright © 2021 The Korean Movement Disorder Society  1
Encephalopathy and Complex Hyperkinesia  
in a Patient with Severe Acute Respiratory  
Syndrome Coronavirus-2 Infection
Wenyang Li,1,2 Elif Pinar Coskun,1,2 Rolando Berger,2,3 John Thomas Slevin,1,2 Luther Creed Pettigrew1,2
1Department of Neurology, Kentucky Neuroscience Institute, University of Kentucky Chandler Medical Center, Lexington, KY, USA 
2Neurology and Pulmonary Medicine Services, Lexington Veterans Administration Health Care System, Troy Bowling Campus, Lexington, KY, USA 
3Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, University of Kentucky Chandler Medical Center, Lexington, KY, USA
https://doi.org/10.14802/jmd.20084  /  J Mov Disord  2021 Jan 12 [Epub ahead of print]
pISSN 2005-940X / eISSN 2093-4939
JMD
Dear Editor,
In December 2019, several cases of atypical pneumonia were 
reported in Wuhan, China.1 A zoonotic beta-coronavirus, severe 
acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was 
identified as the causative agent.2 Neurological complications 
have been reported during the ensuing worldwide pandemic, 
defined by the World Health Organization as the 2019 novel 
coronavirus disease (COVID-19). Filatov et al.3 described CO-
VID-19 encephalopathy with sharply contoured frontal waves 
on electroencephalography. Vollono et al.4 reported focal status 
epilepticus (SE) in a SARS-CoV-2-infected patient. We describe 
a case of SARS-CoV-2 infection complicated by encephalopathy 
and transient, complex hyperkinesia.
A 74-year-old African American man was admitted to the Vet-
erans Affairs Hospital in Lexington, Kentucky, after two days 
of nonpurulent cough, malaise, shortness of breath, and liquid 
stools. The medical history was notable for hypertension, diabetes 
mellitus, and chronic renal insufficiency. The patient was febrile 
(39°C), tachypneic, and tachycardic. Neurological examination 
revealed distal symmetric polyneuropathy. Admission laboratory 
studies showed mild anemia, thrombocytopenia, absolute gran-
ulocytosis and lymphocytopenia, and elevated serum creatinine 
(Supplementary Table 1 in the online-only Data Supplement). 
Testing for the viral genome of SARS-CoV-2 by a nasopharyn-
geal swab was positive, as was a fecal screen for Clostridium dif-
ficile. The patient was started on oral vancomycin.
On the fourth hospital day, the patient became acutely hypox-
ic and was intubated. Hydroxychloroquine and broad-spec-
trum antibiotics were started. Within 18 hours after intubation, 
the patient developed asynchronous myoclonic jerks of the ex-
tremities, which lasted for 10 minutes. Three hours later, multil-
imb myoclonic jerks recurred and persisted, despite boluses of 
benzodiazepine and intravenous (IV) loading of levetiracetam. 
With the patient lying supine, one side of the pelvis was observed 
to lift repetitively, followed by the same movement on the other 
side. The patient remained on midazolam infusion and was IV 
loaded with fosphenytoin, which caused the adventitious move-
ments to abate. Hydroxychloroquine was discontinued. 
A noncontrast CT scan of the brain showed no acute intracra-
nial lesion, and a chest CT scan revealed pneumonia (Figure 1). 
The patient was treated empirically with IV acyclovir, ampicil-
lin, ceftriaxone, and vancomycin. Two IV doses of tocilizumab 
were administered to treat the cytokine storm associated with 
SARS-CoV-2 infection. Lung-protective ventilation was initiat-
ed, with the patient alternating from supine to prone position. 
On the sixth hospital day, spinal fluid was obtained by lumbar 
puncture and showed no evidence of encephalitis (Supplemen-
tary Table 1 in the online-only Data Supplement). On the seventh 
day, worsening renal insufficiency prompted the initiation of 
hemodialysis by continuous renal replacement therapy (CRRT). 
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Lung-protective ventilation was halted.
On the 22nd hospital day, nonconvulsive SE was suspected. 
Conjugate gaze was deviated to the right. There were no ob-
served adventitious movements. A brain CT scan was repeated 
with/without contrast and was unremarkable. Bedside electro-
encephalography revealed low-voltage, generalized slowing but 
no epileptiform activity. 
The patient was re-examined on the 35th hospital day, 48 hours 
after sedation was withdrawn. Levetiracetam was discontinued 
in response to markedly elevated liver enzymes. The patient was 
able to visually attend and blink to threat but would not follow 
verbal commands. There was no gaze restriction or extraocular 
muscle palsy in the horizontal plane. There was no observed nys-
tagmus or oculogyrus. The patient was noted to have few spon-
taneous movements of the upper limbs. Fasciculations were not 
identified. Biceps reflexes were graded as 1+/4+, bilaterally and 
symmetrically. In the lower limbs, the patellar reflexes were graded 
as 2+/4+ with sustained ankle clonus. Extensor plantar signs could 
not be elicited. A noncontrast brain CT scan was unrevealing. 
The patient was observed to have intermittent facial dyskine-
sias, which included symmetric contractions of the frontalis mus-
cles with eyebrow raising, forceful blinking, “fish-mouthing” with 
repetitive opening and closing of the lips, and puffing of the cheeks. 
The head would also laterally rotate to the right, and myoclonic 
contracture of the rectus abdominus muscles would occur. At in-
tervals, the patient would engage in a complexly patterned mo-
tor activity that would begin with pelvic thrusting and splaying 
of the legs, followed by short bursts of repetitive myoclonic in-
versions of the knees (Supplementary Video 1 and 2 in the on-
line-only Data Supplement). 
One week later, the hyperkinetic movements lessened. The 
patient would attend visually and communicate by a head nod. 
The left arm was plegic and hyporeflexic. The fingers of the right 
hand were flexed, and the wrist extended in response to central 
nociception. There was increased motor tone in the legs, with 
crossed adduction of the knees and bilateral sustained ankle 
clonus. 
During the prolonged hospitalization, the patient received IV 
infusions of methylprednisolone and high-dose dexamethasone. 
On the 43rd hospital day, the patient received an infusion of 
convalescent plasma donated by a COVID-19 survivor. On the 
50th hospital day, the first of the two serial COVID-19 swabs 
tested negative. The patient was transferred to a rehabilitation 
facility on the 62nd hospital day.
Our patient developed febrile viral pneumonia due to SARS-
CoV-2 infection, complicated by C. difficile colitis and acute-on-
chronic renal insufficiency, which was corrected with CRRT. 
Admission laboratory studies revealed thrombocytopenia and 
lymphocytopenia, which have been observed in cases of severe 
SARS-CoV-2 infection.5 Elevated creatine kinase levels indicated 
the potential for virally mediated muscle injury, a reported neu-
rological complication of COVID-19.5 As the infectious syndrome 
progressed in severity, our patient incurred rising levels of plas-
ma D-dimer and ferritin, which have become recognized prog-
nostic markers of a poor outcome.
This is the first report of encephalopathy with complex hyper-
Figure 1. Noncontrast brain CT scan obtained on the 22nd hospital day, showing no infarct or hemorrhage within the deep gray nuclei and 
the thalami (A); noncontrast chest CT scan obtained on the 36th hospital day, revealing ground-glass opacities in the posterior region of the 
chest (B).
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kinesia as a neurological complication of SARS-CoV-2 infection. 
The complex hyperkinetic movements observed after the 35th 
hospital day appeared to follow marked elevations of plasma fer-
ritin and CRP, considered biomarkers of the SARS-CoV-2-me-
diated cytokine activity. Rábano-Suárez et al.6 reported three 
cases of generalized myoclonus in COVID-19 that appeared to 
occur temporally after viral-induced cytokine storms.
We concede that the first noted occurrence of repetitive myo-
clonic limb movements may have represented SE, as reported 
by Vollono et al.4 The complexly patterned adventitious move-
ments observed on the 35th hospital day were not epileptic; the 
myoclonic activity may have been caused by hepatic or renal 
encephalopathy. With hyporeflexia and bicrural paresis that af-
fected the upper limbs after prone ventilation, we speculate that 
our patient experienced bibrachial neuritis and/or stretch inju-
ry to the brachial plexus, as reported by Diprose et al.7 
Supplementary Video Legends
Video 1. In the video clip (1.08 minutes) obtained on the 45th hospital day, 
there is bilateral arm weakness with a wrist drop shown in the right limb. The 
patient engages in splaying movements of the legs, followed by short bursts 
of myoclonic knee adduction. 
Video 2. In the video clip (50 seconds), there are magnified views of the 
myoclonic knee adduction.
Supplementary Materials
The online-only Data Supplement is available with this article at https://
doi.org/10.14802/jmd.20084.
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WBC, ×103/μL (5.0–10.0) 6.5 5.5 4.4 4.3 7.5 11.5 16.6 6.9 11.5
Hgb (g/dL)/Hct (%) (14–18)/(42–52) 14.4/44.2 13.9/43.0 12.6/39.7 11.2/35.5 11.9/37.9 7.0/22.2 7.4/23.8 8.7/28.8 7.7/25.1
Platelets, ×103/μL (150–450) 124 78 89 92 129 207 316 237 233
Absolute granulocyte, % (42–75) 65.8 77.6 72.2 67.1 85 - 86.4 67.7 -
Absolute lymphocyte, % (22–44) 24.1 15 24 28.1 11.1 - 5.9 17.3 -
Absolute granulocyte, ×103/μL (1.4–6.5) 4.25 4.25 3.19 3.19 6.37 - 14.3 4.68 -
Absolute lymphocyte, ×103/μL (1.2–3.4) 1.56 0.82 1.06 1.2 0.83 - 0.98 1.20 -
Coagulation
PT (sec)/INR (11.5–14)/(0.91–1.16) - - 12.6/1.02 12.7/1.03 12.4/1.00 14.1/1.17 - 13.5/1.11 -
Activated PTT, sec (22.4–33.7) - - - - 34.2 - - - -
Fibrinogen, mg/dL (224–537) - - - - 620 - 1,060 - -
D-dimer, µg/mL FEU (plasma; 0–0.5) - - 3.43 3.77 2.69 3.7 4.66 - -
Ferritin, ng/mL (plasma; 21.8–274.7) - - 2,913.8 4,051.3 4,622.2 1,779.9 2,431 - -
Systemic inflammation/metabolism
CRP, mg/L (plasma; 0–5.0) - - 173.4 224 160.7 28.3 264.5 - -
Sedimentation rate, mm/hr (0–20) - - - 49 - - - - -
ANA (serum; < 1:40) - - - - - - - < 1:40 -
c-ANCA (serum; < 1:20) < 1:20 -
p-ANCA (serum; < 1:20) < 1:20 -
Metabolism and nutrition
Hgb A1c, % (4.4–6.4) 9.0 - - - - - - - -
LDH, U/L (125–220) - - - 500 634 - -
CK, IU/L (plasma; 30–200) - - 349 321 - - 59 - -
Lactic acid (plasma; 0.5–2.2) - - - - - - 0.7 - -
Vitamin B12, pg/mL (plasma; 213–816) - - - - - 1693 - - -
Vitamin B1, nmol/L (whole blood; 66.5–200) - - - - - 90.8 - - -
Vitamin D 25-hydroxy, ng/mL (serum; 30–100) - - - - - 16.9 - - -
Renal function
Blood urea nitrogen, mg/dL (serum; 9–25) 25 26 59 70 80 66 77 56 47
Total creatinine, mg/dL (serum; 0.72–1.25) 1.8 2.05 3.55 5.05 6.6 2.94 2.33 1.81 2.3
eGFR, mL/min/1.73 m2 (> 60) 45 39 20 14 10 25 33 45 34
Liver function
Total bilirubin, mg/dL (0.2–1.2) 0.3 0.9 0.4 0.3 0.2 0.4 2.2 2.2 1.2
Direct bilirubin, mg/dL (0–0.5) - 0.3 0.3 - - 0.3 1.9 1.6 -
AST, U/L (5–34) 35 43 83 71 58 138 387 216 124
ALT, U/L (0–55) 32 35 47 40 32 343 571 400 230
Alkaline phosphatase, U/L (40–150) 75 55 47 45 44 311 698 1,257 943
Ammonia, µmol/L (plasma; 18–72) - - - - - 48 - - -
Infectious disease
COVID-19 screen PCR (naso-pharyngeal swab) - Positive - - - Positive Positive Negative -
Influenza A PCR (naso-pharyngeal swab) - Negative - - - - - - -
Influenza B PCR (naso-pharyngeal swab) - Negative - - - - - - -
Respiratory syncytial virus (naso-pharyngeal swab) - Negative - - - - - - -
MRSA (nares) - Negative - - - - - - -
Hepatitis B (serum) - - - - - - Not detected - -
Hepatitis B surface antigen - - - - - - Not detected - -
Hepatitis C - - - - - - Not detected - -
CMV IgG (serum) - - - - - - - Positive -
CMV IgM (serum) - - - - - - - Negative -
HIV Ab/Ag screen (serum) - - - - - - Negative
Aerobic/anaerobic blood cultures - No growth at 48 hrs No growth at 48 hrs - - - - - -
Spinal fluid
Cell count - - -
5 nucleated cells/µL 
(99% mono)
- - - - -
Protein, mg/dL (15–45) - - - 49 - - - - -
Gram stain/India ink stain - - - Negative - - - - -
Bacterial culture - - - Negative - - - - -
Meningitis/encephalitis panel - - - Negative - - - - -
Fungal culture - - - No growth × 1 week - - - - -
Cryptococcal Ag screen - - - Negative - - - - -
Viral culture - - - No growth × 1 week - - - - -
HSV-1/2 DNA (PCR) - - - Negative - - - - -
WBC: white blood cell, PT: prothrombin time, INR: International Normalized Ratio, PTT: partial thromboplastin time, CRP: C-reactive protein, LDH: lactate dehydrogenase, CK: creatine kinase, ANA: anti-nuclear antibody, c-ANCA: cytoplasmic anti-neu-
trophil cytoplasmic antibodies, p-ANCA: perinuclear anti-neutrophil cytoplasmic antibodies, eGFR: estimated glomerular filtration rate, AST: aspartate aminotransferase, ALT: alanine transaminase, COVID-19: 2019 novel coronavirus disease, PCR: poly-
merase chain reaction, MRSA: methicillin-resistant Staphylococcus aureus, CMV: cytomegalovirus, HIV: human immunodeficiency virus, HSV: Herpes simplex virus.
